Huateng Pharmaceutical, a global supplier of pharmaceutical Intermediates, offers Irbesartan Intermediates 2-n-Butyl-1,3-diaza-spiro[4,4]non-1-en-4-one HCl (CAS NO. 151257-01-1) for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation.
Application: 2-Butyl-1,3-diazaspiro[4.4]non-1-en-4-one is an intermediate of Irbesartan (Avapro) (I751000).
*The following content is generated by AI and is for reference only.
2-n-Butyl-1,3-diaza-spiro[4,4]non-1-en-4-one hydrochloride is a specialized heterocyclic compound belonging to the spirocyclic urea class, widely recognized in medicinal chemistry and organic synthesis research. With the molecular formula C12H21ClN2O and a CAS registry number of 100987-68-8, this salt form offers enhanced solubility and stability compared to its free base counterpart, making it highly suitable for biological assays and pharmaceutical development. The molecule features a unique spiro-fused structure where a five-membered diazolidinone ring intersects with a six-membered cyclohexane ring at a single carbon atom, while an n-butyl substituent provides lipophilic character essential for membrane permeability studies.
Primarily utilized as a key intermediate in the synthesis of complex bioactive molecules, this compound serves as a versatile scaffold for developing novel therapeutics targeting various diseases. Its structural motif closely resembles that of potent HIV protease inhibitors and other enzyme modulators, allowing researchers to explore structure-activity relationships (SAR) effectively. In drug discovery pipelines, 2-n-butyl-1,3-diaza-spiro[4,4]non-1-en-4-one HCl is frequently employed to construct libraries of spirocyclic derivatives aimed at improving pharmacokinetic profiles, including metabolic stability and oral bioavailability. Furthermore, its presence in the hydrochloride salt form ensures reliable handling during high-throughput screening processes, minimizing variability caused by hygroscopicity or decomposition.
Beyond oncology and antiviral research, this compound finds applications in agrochemical development, where spirocyclic structures are increasingly valued for their pest control efficacy and environmental safety. The rigid geometry of the spiro center restricts conformational flexibility, often leading to higher binding affinity and selectivity against specific protein targets. Researchers leverage these properties to design next-generation inhibitors with reduced off-target effects. As a commercially available reagent, it supports academic institutions and pharmaceutical companies in advancing preclinical studies. Its role extends to methodological innovations in asymmetric synthesis and chiral resolution techniques. Overall, 2-n-butyl-1,3-diaza-spiro[4,4]non-1-en-4-one HCl represents a critical building block bridging fundamental organic chemistry with practical therapeutic applications, driving innovation in modern drug design and chemical biology.